Current Perspectives on the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Listen Now

Topics Covered

• Review of Chronic Lymphocytic Leukemia
• Significant Role of Testing in Informing Your Treatment Choices
• First-Line Treatment Options
• Treatment of Relapsed & Refractory CLL
• Re-Testing Importance in Determining Treatment for 2nd & 3rd Line Treatments
• Current Perspectives on New & Emerging Treatments of CLL
• Updates on Clinical Trials & Their Significance for CLL
• Key Questions to Ask & Re-Ask Your Health Care Team
• Practical and Psychosocial Support to Cope with CLL
• Questions for Our Panel of Expert

Our Panel of Experts

Christine Ryan, MD

Physician, Division of Lymphoma, Center for Chronic Lymphocytic Leukemia (CLL), Instructor in Medicine, Harvard Medical School, Dana-Farber Cancer Institute

Christopher Jensen, MD, MSCR

Clinical Assistant Professor, Lymphoma Program, University of North Carolina-Chapel Hill

Paul J. Hampel, MD

Assistant Professor of Medicine and Oncology, Mayo Clinic Comprehensive Cancer Center

Fernando Parra Chong

Strategic Partnerships Manager, CLL Society

Carolyn Messner, DSW, BCD, FAPOS, FAOSW

Senior Director of Education and Training, CancerCare

Brochure

You can download the brochure for this workshop

Workshop Date

This workshop was originally recorded on March 28, 2025.